Johnson & Johnson: Cardiovascular Diseases trials
The registry lists 10 Cardiovascular Diseases studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 2 1Phase 3 2Phase 4 1No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac RecoveryRecruitingNCT06965504Not applicable
- The Fibrin Pad CV Phase III StudyCompletedNCT02040428Phase 3Results posted
- The Fibrin Pad Cardiovascular StudyCompletedNCT01681030Phase 2Results posted
- Atrial Fibrillation Progression TrialTerminatedNCT01570361Phase 4Results posted
- CANVAS - CANagliflozin cardioVascular Assessment StudyCompletedNCT01032629Phase 3Results posted
- The RECOVER IV TrialTerminatedNCT05506449Not applicable
- Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular FunctionActive, not recruitingNCT04763200Not applicable
- The Global cVAD StudyActive, not recruitingNCT04136392
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseCompletedNCT03492580
- Care China-DiabetesTerminatedNCT00938119